Brind.
  1. Tariffs and onshoring trends benefit AI stocks, while Lexeo Therapeutics receives Breakthrough Therapy designation for gene therapy targeting Friedreich ataxia.

A gene therapy for Friedreich ataxia has been designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.

1 report, 0 independent Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

A gene therapy for Friedreich ataxia has been designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.

Who's involved

What this event is mainly about
Donald TrumpBiogen

Keep exploring

Part of

Tariffs and onshoring trends benefit AI stocks, while Lexeo Therapeutics receives Breakthrough Therapy designation for gene therapy targeting Friedreich ataxia. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet